AffiliationUniversity of Surrey, Guildford, UK.
MetadataShow full item record
AbstractThe hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only have such rational approaches in drug design yielded several key therapeutics, such outputs have also offered insights into the integrated mechanistic aspects of basic and clinical research at the genetics level for the future. In no other area of medical research have the effects of such work been felt, than in cancer research, through targeting the BAX-Bcl-2 protein-protein interactions. With these promising outputs in mind, several mimetics, and their potential therapeutic applications, have also been developed for several other pathological conditions, such as cardiovascular disease and tissue fibrosis, thus highlighting the universal importance of the intrinsic arm of the apoptosis pathway and its input to general tissue homeostasis. Considering such recent developments, and in a field that has generated so much scientific interest, we take stock of how the broadening area of BH3-mimetics has developed and diversified, with a focus on their uses in single and combined cancer treatment regimens and recently explored therapeutic delivery methods that may aid the development of future therapeutics of this nature.
CitationTownsend PA, Kozhevnikova MV, Cexus ONF, Zamyatnin AA Jr, Soond SM. BH3-mimetics: recent developments in cancer therapy [Internet]. Vol. 40, Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2021.
JournalJournal of Experimental and Clinical Cancer Research
- Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
- Authors: Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A
- Issue date: 2011 Jul 15
- Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
- Authors: Ewald L, Dittmann J, Vogler M, Fulda S
- Issue date: 2019 Dec 4
- A direct comparison of selective BH3-mimetics reveals BCL-X<sub>L</sub>, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma.
- Authors: Bierbrauer A, Jacob M, Vogler M, Fulda S
- Issue date: 2020 May
- Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
- Authors: Yu L, Liu S
- Issue date: 2013 Dec
- B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
- Authors: Renault TT, Elkholi R, Bharti A, Chipuk JE
- Issue date: 2014 Sep 19